← All Posts
KER
Keros Therapeutics, Inc.
June 04, 2026
•
Author: Phil Ratcliff
| Item |
Proposal |
Vote |
| 1 |
To elect two (2) nominees for Class III director, Jean-Jacques Bienaimé and Charles Newton, each to hold office until the 2029 Annual Meeting of Stockholders and until their successors are duly elected and qualified. |
✓ For(571.43)
|
| 2 |
To ratify the selection by the Audit Committee of the Board of Directors of Deloitte & Touche LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2026. |
✓ For(571.43)
|
| 3 |
To approve, on an advisory basis, the compensation of the Company’s named executive officers as disclosed in the proxy statement. |
✓ For(571.43)
|
This article was written for information purposes only and its content should not be
construed by any consumer and/or prospective client as rebel Financial's solicitation
to affect, or attempt to affect transactions in securities, or the rendering of
personalized investment advice for compensation. No client or prospective client should
assume that any such discussion serves as the receipt of, or a substitute for,
personalized advice from rebel Financial, or from any other investment professional.
See our disclosures page for more information.
rebel Financial